The Karolinska KI/K COVID-19 Immune Atlas aims to provide a comprehensive overview of the human immune response in COVID-19 disease, freely available for scientists, both in academia, in other organizations, and in industry. Read more about the project

    The project

    The Karolinska KI/K COVID-19 Immune Atlas project was initiated in April 2020, with the aim to provide a comprehensive overview of the human immune response in COVID-19 disease. The data in this open resource will allow scientists, both in academia, in other organizations, and in industry, to freely explore the nature of the immune response. The Immune Atlas contains analysis of different immune and inflammatory cells, or group of cells, as well as soluble factors. The Karolinska KI/K COVID-19 Immune Atlas project has been funded by the Knut and Alice Wallenberg Foundation and a donation from Nordstjernan AB.

    Cohort
    Cells
    Flow panels

    The cohort

    The Karolinska KI/K Covid-19 Immune Atlas contains peripheral blood-derived cell and soluble factor data from hospitalized Covid-19 patients grouped into different stages of disease severity. Samples were collected once a week upon three consecutive weeks in April and May 2020 at the Karolinska University Hospital Infectious Diseases and Intensive Care Unit Clinics, and were directly processed and analyzed at the Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden. Data are presented in an aggregated form.

    Patient characteristics

    The Covid-19 patients analyzed were stratified in two groups according to set inclusion and exclusions criteria. All included patients (ages 18 to 78 years old) were SARS-CoV-2 RNA positive and sampled 5 to 24 days after symptom debut and 1–8 days after hospital admission. Moderately sick patients had a saturation of 90–94% or were receiving 0.5–3 L/min of oxygen. Severely sick patients were treated in an intensive care unit or a high dependency unit. Patient with current malignancy immunomodulatory treatment prior to hospitalization were excluded. Detailed clinical characteristics are presented in the table below. Non Covid-19 controls were age and sex matched, SARS-CoV-2 IgG seronegative at time of inclusion.

    • Clinical characteristics
    • Clinical laboratory results
    Clinical characteristics of COVID-19 patients in immune atlasModerateSevere
    Group sizen1017
    Risk factorsAge, median (range)56.5 (18 - 76)58 (40 - 78)
    Sex, n (female/male)3/73/14
    BMI, median (range)27.63 (23 - 35,06)29 (23 - 55)
    Smoking – Current, n (%)1 (10)2 (12)
    - Prior, n (%)2 (20)5 (29)
    - Non-smoker, n (%)2 (20)9 (53)
    - Unknown, n (%)5 (50)1 (6)
    Preexisting conditions, n (%)None4 (40)5 (29)
    Diabetes mellitus3 (30)5 (29)
    Hypertension2 (20)6 (35)
    Coronary heart disease-2 (12)
    Asthma1 (10)2 (12)
    OtherOSAS, ischemic heart disease, lymphomaChronic hepatitis B, OSAS, renal failure
    Viremia at sampling, n (%) 4 (40)8 (47)
    Symptoms on admissionFever, n (%)10 (100)17 (100)
    Cough, n (%)9 (90)14 (82)
    Dyspnea, n (%)10 (100)17 (100)
    Body ache, n (%)3 (30)9 (53)
    Gastrointestinal, n (%) 1 (10)3 (18)
    Days from symptom onset to admission, median (range)8.5 (4 - 14)9 (3 - 14)
    Days from symptom onset to sampling, median (range)13.5 (6 - 19)14 (5 - 24)
    Peak supportive oxygen therapyNone, n (%)2 (20)0 (0)
    Low flow <10L/min, n (%)6 (60)0 (0)
    Low flow 10-15 L/min, n (%)1 (10)3 (18)
    High Flow, n (%)1 (10)1 (6)
    Venitlator, n (%)0 (0)12 (71)
    ECMO, n (%)0 (0)1 (6)
    PF ratio, median mmHg (range)357 (312 - 523)137 (52 - 285)
    Supportive oxygen therapy, median in days (range)2 (0 - 51), 1 ongoing after discharge21 (8 - 45), 1 ongoing at hospital
    Treatment prior to sampling, n (%)Anticogulant treatment10 (100)15/17 (14 LWMH, 1 oral anticoagulation, 1 unknown)
    Corticosteroids2 (20)12 (71)
    Antibiotics3 (30)12 (71)
    Antivirals / Cytokine inhibitors0 (0)3 (18): Remdesivir, Anakinra, Tocilizumab
    Clinical courseDays on ICU, median (range)0 (0)14 (0 - 45), 1 ongoing
    Days intubated, median (range)0 (0)11 (0 - 45), 1 ongoing
    Days hospitalised, median (range)8 (5 - 39)21 (10 - 57), 1 ongoing
    Radiological bilateral infiltrations, n (%)6 (60), 4 N/A15 (88), 2 N/A
    Positive bloodcultures, n (%)0 (0)4 (24)
    Positive culture from tracheal aspirate, n (%)0 (0)7 (41)
    Embolism/thrombosis, n (%)0 (0)4 (24): 2x Pulmonary embolism, 1 deep vein thrombosis and 1 arterial thrombosis
    SOFA score at sampling, median (range)1 (0 - 2)6 (2 - 12)
    Outcome, n (%)Discharged10 (100)12 (71), 1 still hospitalised
    Death0 (0)4 (24)
    Before study samplingNormal distributionModeratemedian peak (range)Severe/Criticalmedian peak (range)p-value
    C-reactive protein, mg/L<3148 (34 - 346)296 (101 - 452)0.015
    Procalcitonin, μg/L<0.50.28 (0.11 - 66)0.90 (0.19 - 10)0.10
    D-dimer, mg/L<0.560.72 (0.28 - 1.5)2.3 (0.58 - 5.4)<0.001
    Ferritin, μg/L10-150856 (219 - 3570)1793 (183 - 5500)0.074
    Fibrinogen, g/L2-4.2N/A7.05 (4.1 - 10.2)
    Lactate dehydrogenase, μkat/L<3.5 5.6 (3.8 - 13.7)10.6 (0.89 - 23)0.003
    Alanine aminotransferase, μkat/L<0.760.67 (0.51 - 3.43)1.24 (0.51 - 13.8)0.16
    Bilirubin, μmol/L<268 (4 - 11)12 (7 - 81)0.002
    Creatinine, μmol/L<9075 (49 - 168)90 (46 - 326)0.20
    Prothrombin complex, INR<1.21.0 (0.9 - 1.1)1.1 (0.9 - 2.1)0.005
    Troponin T, ng/L<1511 (5 - 218)19 (8 - 601)0.037
    Myogloblin, μg/L<7323 (22 - 37)369 (36 - 6400)0.001
    Platelet count, highest, x109/L165-387 296 (152 - 642)398 (149 - 770)0.31
    Platelet count, lowest, x109/L165-387232 (131 - 342)196 (110 - 330)0.86
    Lymphocytes, lowest, x109/L1.1-3.50.8 (0.3 - 1.9)0.6 (0.2 - 1.5)0.040
    Neutrophils, lowest, x109/L1.6-5.94.0 (0.5 - 6.8)4.4 (1.7 - 15.9)0.13
    At study sampling (+/-24h)Normal distributionModeratemedian peak (range)Severe/Criticalmedian peak (range)p-value
    C-reactive protein, mg/L<3104 (20 - 394)203 (37 - 346)0.11
    Procalcitonin, μg/L<0.50.39 (0.12 - 866)0.52 (0.16 - 10)0.59
    Leukocytes, highes, x 109/L3.5-8.8 7.7 (1.5 - 12.6)12.5 (4 - 18.4)0.005
    Leukocytes, lowest, x 109/L3.5-8.86.2 (1 - 10.5)9.2 (2.3 - 15.7)0.013
    Neutrophils, highest, x 109/L1.6-5.9L5.4 (0.9 - 9.3)10.9 (3.2 - 16.7)0.001
    D-dimer, mg/L<0.560.71 (0.36 - 1.3)2.3 (0.44 - 7.6)0.001
    Ferritin, μg/L10-150738 (161 - 1971)1832 (183 - 4306)0.053
    Fibrinogen, g/L2-4.2N/A6.4 (3.5 - 10.2)
    Bilirubin, μmol/L<266 (4 - 11)9 (6 - 81)0.049
    Creatinine, μmol/L<9068 (43 - 168)73 (36 - 326)0.47
    Prothrombin complex, INR<1.21.0 (1 - 1.1)1.1 (0.9 - 1.4)0.32
    Troponin T, ng/L<156 (5 - 43)18 (6 - 434)0.018
    Haemoglobin, lowest, g/L117-153124 (90 - 145)113 (73 - 146)0.19
    Lymphocytes, lowest, x 109/L1.1-3.51.2 (0.3 - 2.4)0.8 (0.3 - 2.3)0.023
    Albumin, lowest, g/L36-4828 (21 - 37)19 (16 - 29)0.003
    Platelet count, lowest, x 109/L165-387324 (131 - 642)361 (146 - 579)0.49
    At study sampling (+/-5d)Normal distributionModeratemedian peak (range)Severe/Criticalmedian peak (range)p-value
    Interleukin-6, ng/L<758 (2 - 151)198 (29 - 8093)0.041
    Interleukin-1β, ng/L<5N/A9.6 (5.4 - 16.8)
    Interleukin-10, ng/L<5N/A24 (5.6 - 58)
    Tumor necrosis factor-α, ng/L<12N/A15 (8 - 48)

    Cells

    Cell data include studies of innate lymphoid cells (ILCs), natural killer (NK) cells, conventional T cells, unconventional T cells (MAIT cells, γδ T cells, DNT cells), B cells, granulocytes, monocytes, and DCs as well as soluble factors. Analysis provided include data from up to 29 color flow cytometry panels. Soluble factor data include serum analysis by high-quality multiplex immunoassay panels. Data are presented in an aggregated manner, and allow for analysis and comparison visualized by different means such as box plots, volcano plots, radar charts, and with applicable statistical measure terms.

    Panels

    Many factors have been considered when designing the used panels for flow cytometry including biomarker selection, instrument configuration, flourochrome brightness, spectral overlap, antigen density, antigen co-expression, and reagent availability. Up to 29 different parameters have been analyzed pending on cell-type analyzed and specific information desired. Panels used for the analysis are shown per cell-track.

    • NK cells
    • T cells
    • Unconventional T cells
    • ILCs
    • DCs and monocytes
    LaserFilterAntigen and fluorochrome
    355379/28 HLA-DR BUV395
    515/30 CD16 BUV496
    580/20 CD56 BUV563
    605/20 NKG2D BUV615
    670/25 CD38 BUV661
    735/50 CD69 BUV737
    810/40 CD45 BUV805
    405450/50 MIP1β BV421
    525/50 CD14 V500, CD19 V500, CD123 BV510, DCM Aqua
    586/15 empty
    605/40 KLRG1 BV605
    677/20 TIGIT BV650
    710/50 KIR3DL1
    750/30 IFNγ BV750
    810/40 CD25 BV786
    488530/30 CD98 BB515
    610/20 NKG2C BB630
    670/30 CXCR6 BB660
    710/50 Tim-3 BB700
    750/30 Perforin BB755
    810/40 Granzyme B BB790
    561586/15 Ksp37 PE
    610/20 CD62L ECD
    670/30 CD3 PE-Cy5
    710/50 KIR2DL2/S2/L3 PE-Cy5.5
    780/60 NKG2A PE-Vio770
    637670/30 KIR2DL1 APC
    730/45 Ki67 AF700
    780/60 CD57 APC-Vio770
    LaserFilterAntigen and fluorochrome
    355379/28 CD8 BUV395
    515/30 CD38 BUV496
    580/20 CD28 BUV563
    605/20 HLA-DR BUV615
    670/25 Lag-3 BUV661
    735/50 TIGIT BUV737
    810/40 CD3 BUV805
    405450/50 A02:01 GL9 EBV or NV9 CMV BV421
    525/50 CD14 BV510, CD19 BV510, DCM Aqua
    586/15 CD45RA BV570
    605/40 CD127 BV605
    677/20 Tim-3 BV650
    710/50 CD39 BV711
    750/30 CD69 BV750
    810/40 CD27 BV786
    488530/30 TCF1 A488
    610/20 CD95 BB630
    670/30 Ki-67 BB660
    710/50 Perforin BB700
    750/30 CTLA-4 BB755
    810/40 Granzyme BB790
    561586/15 A02:01 RK9 or LL9 SARS-CoV-2 Dextramer PE
    610/20 2B4 PE/Dazzle™594
    670/30 CD25 PE-Cy5
    710/50 CD4 PE-Cy5.5
    780/60 PD-1 PE-Cy7
    637670/30 TOX Alexa647
    730/45 CXCR5 APC-R700
    780/60 CCR7 APC-H7
    LaserFilterAntigen and fluorochrome
    355379/28 CD69 BUV395
    515/30 CD38 BUV496
    580/20 empty
    605/20 empty
    670/25 empty
    735/50 CD56 BUV737
    810/40 CD3 BUV805
    405450/50 PD1 BV421
    525/50 CD14 V500, CD19 V500
    586/15 CD8 BV570
    605/40 IL7R BV605
    677/20 CXCR3 BV650
    710/50 CD4 BV711
    750/30 Va24 BV750
    810/40 HLA-DR BV785
    488530/30 Ki67 AF488
    610/20 empty
    670/30 empty
    710/50 Granzyme A PerCP-Cy55
    750/30 empty
    810/40 empty
    561586/15 MR1-5-OP-RU tetramer
    610/20 TCRgd PEDazzle 594
    670/30 CD161 PeCy5
    710/50 empty
    780/60 Va7.2 PE-Cy7
    637670/30 CXCR6 AF647
    730/45 Granzyme B AF700
    780/60 DCM IR
    LaserFilterAntigen and fluorochrome
    355379/35 CD45 BUV395
    740/35 CCR6 BUV737
    405450/50 CXCR3 BV421
    525/50 CCR4 BV510
    585/42 CD3 BV570
    610/20 CD161 BV605
    670/30 CD69 BV650
    710/50 CD56 BV711
    780/60 CD45RA BV785
    488530/30 CD1a FITC, CD14 FITC, CD19 FITC, CD34 FITC, CD123 FITC, BDCA2 FITC, FcER1 FITC, TCRab FITC, TCRgd FITC, DCM green
    561586/15 HLA-DR PE
    610/20 CRTH2 PECF594
    661/20 NKp44 PE-Cy5
    710/50 CD117 PE-Cy5.5
    780/60 CD127 PE-Cy7
    639670/30 NKG2A APC
    730/45 Ki67 A700
    780/60 CD62L APC-Cy7
    LaserFilterAntigen and fluorochrome
    355379/28 CD123 BUV395
    515/30 AXL BUV496
    580/20 CD147 BUV563
    605/20 CCR2 BUV615
    670/25 CD38 BUV661
    735/50 CD16 BUV737
    810/40 CD86 BUV805
    405450/50 CD200R BV421
    525/50 CD15 BV510, DCM aqua
    586/15 CD44 BV570
    605/40 FceR1 BV605
    677/20 CD163 BV650
    710/50 CD141 BV711
    750/30 CD7/34/19/3 BV750
    810/40 HLA-DR BV785
    488530/30 CD206 BB515
    610/20 empty
    670/30 empty
    710/50 CD1c BB700
    750/30 empty
    810/40 empty
    561586/15 CD116 PE
    610/20 CD126 PE/Dazzle™594
    670/30 CD5 PE-Cy5
    710/50 c-KIT PE-Cy5.5
    780/60 CD88 PE-Cy7
    637670/30 CLEC9A Alexa647
    730/45 CD45RA AF700
    780/60 CD14 APC-Cy7

    People

    Below we list individuals involved in the Karolinska KI/K COVID-19 Immune Atlas Project including scientists, physicians, physician scientists, and support personnel.

    NameAffiliation
    John Tyler SandbergCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    Helena BergstenCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    Niklas K BjörkströmCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    Susanna BrighentiCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    Marcus BuggertCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    Marta ButrymCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    Benedict ChambersCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    Puran ChenCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    Martin CornilletCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    Angelica Cuapio GomezCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    Isabel Diaz LozanoCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    Majda DzidicCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    Johanna EmgårdCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    Malin Flodström-TullbergCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    Jean-Baptiste GorinCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    Sara Gredmark-RussCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    Alvaro Haroun-IzquierdoCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    Laura HertwigCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    Sadaf KalsumCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    Jonas KlingströmCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    Efthymia KokkinouCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    Egle KvedaraiteCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    Hans-Gustaf LjunggrenCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    Nicole MarquardtCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    Magdalini LourdaCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    Kimia T MalekiCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    Karl-Johan MalmbergCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    Jakob MichaëlssonCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    Jenny MjösbergCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    Kirsten MollCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    Jagadeeswara Rao MuvvaCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    Anna Norrby-TeglundCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    Laura M Palma MedinaCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    Tiphaine ParrotCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    Lena RadlerCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    Emma RingqvistCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    Johan K SandbergCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    Takuya SekineCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    Tea SoiniCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    Mattias SvenssonCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    Janne TynellCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    Andreas von KriesCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    David WullimannCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    André Perez-PottiCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    Olga Rivera-BallesterosCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    Christopher MaucourantCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    Renata VarnaiteCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    Mira AkberCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    Lena BerglinCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    Demi BrownlieCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    Marco Giulio LoretiCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    Ebba SohlbergCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    Tobias KammannCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    Elisabeth HenrikssonCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    Kristoffer StrålinDepartment of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden
    Soo AlemanDepartment of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden
    Anders SönnerborgDepartment of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden
    Lena DillnerDepartment of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden
    Anna FärnertDepartment of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden
    Hedvig GlansDepartment of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden
    Pontus NauclérDepartment of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden
    Olav RooyackersDepartment of Perioperative Medicine and Intensive Care, Karolinska University Hospital, Stockholm, Sweden.
    Johan MårtenssonDepartment of Perioperative Medicine and Intensive Care, Karolinska University Hospital, Stockholm, Sweden.
    Lars I ErikssonDepartment of Perioperative Medicine and Intensive Care, Karolinska University Hospital, Stockholm, Sweden.
    Björn P PerssonDepartment of Perioperative Medicine and Intensive Care, Karolinska University Hospital, Stockholm, Sweden.
    Jonathan GripDepartment of Perioperative Medicine and Intensive Care, Karolinska University Hospital, Stockholm, Sweden.
    Christian UngeDepartment of Emergency Medicine, Karolinska University Hospital, Stockholm, Sweden

    Papers

    Below we list all papers published, or by other means made public, containing the original data for the Karolinska KI/K COVID-19 Immune Atlas.

    Published

    PNAS. 9 Feb 2021

    Major alterations in the mononuclear phagocyte landscape associated with COVID-19 severity

    Egle Kvedaraite, Laura Hertwig, Indranil Sinha, Andrea Ponzetta, Ida Hed Myrberg, Magda Lourda, Majda Dzidic, Mira Akber, Jonas Klingström, Elin Folkesson, Jagadeeswara Rao Muvva, Puran Chen, Sara Gredmark-Russ, Susanna Brighenti, Anna Norrby-Teglund, Lars I. Eriksson, Olav Rooyackers, Soo Aleman, Kristoffer Strålin, Hans-Gustaf Ljunggren, Florent Ginhoux, Niklas K. Björkström, Jan-Inge Henter, Mattias Svensson, and Karolinska KI/K COVID-19 Study Group

    Clinical & Translational Immunology. 14 Dec 2020

    Innate lymphoid cell composition associates with COVID‐19 disease severity

    Marina García, Efthymia Kokkinou, Anna Carrasco García, Tiphaine Parrot, Laura M Palma Medina, Kimia T Maleki, Wanda Christ, Renata Varnaitė, Iva Filipovic, Hans‐Gustaf Ljunggren, Niklas K Björkström, Elin Folkesson, Olav Rooyackers, Lars I Eriksson, Anders Sönnerborg, Soo Aleman, Kristoffer Strålin, Sara Gredmark‐Russ, Jonas Klingström, Jenny Mjösberg, and the Karolinska KI/K COVID‐19 Study Group

    Science Immunology. 28 Sep 2020

    MAIT cell activation and dynamics associated with COVID-19 disease severity

    Tiphaine Parrot, Jean-Baptiste Gorin, Andrea Ponzetta, Kimia T Maleki, Tobias Kammann, Johanna Emgård, André Perez-Potti, Takuya Sekine, Olga Rivera-Ballesteros, Karolinska COVID-19 Study Group, Sara Gredmark-Russ, Olav Rooyackers, Elin Folkesson, Lars I Eriksson, Anna Norrby-Teglund, Hans-Gustaf Ljunggren, Niklas K Björkström, Soo Aleman, Marcus Buggert, Jonas Klingström, Kristoffer Strålin, Johan K Sandberg

    Science Immunology. 21 Aug 2020

    Natural killer cell immunotypes related to COVID-19 disease severity

    Christopher Maucourant, Iva Filipovic, Andrea Ponzetta, Soo Aleman, Martin Cornillet, Laura Hertwig, Benedikt Strunz, Antonio Lentini, Björn Reinius, Demi Brownlie, Angelica Cuapio Gomez, Eivind Heggernes Ask, Ryan M Hull, Alvaro Haroun-Izquierdo, Marie Schaffer, Jonas Klingström, Elin Folkesson, Marcus Buggert, Johan K Sandberg, Lars I Eriksson, Olav Rooyackers, Hans-Gustaf Ljunggren, Karl-Johan Malmberg, Jakob Michaëlsson, Nicole Marquardt, Quirin Hammer, Kristoffer Strålin, Niklas K Björkström, Karolinska COVID-19 Study Group

    Cell. 14 Aug 2020

    Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19

    Takuya Sekine, André Perez-Potti, Olga Rivera-Ballesteros, Kristoffer Strålin, Jean-Baptiste Gorin, Annika Olsson, Sian Llewellyn-Lacey, Habiba Kamal, Gordana Bogdanovic, Sandra Muschiol, David J. Wullimann, Tobias Kammann, Johanna Emgård, Tiphaine Parrot, Elin Folkesson, Karolinska COVID-19 Study Group, Olav Rooyackers, Lars I. Eriksson, Jan-Inge Henter, Anders Sönnerborg, Tobias Allander, Jan Albert, Morten Nielsen, Jonas Klingström, Sara Gredmark-Russ, Niklas K. Björkström, Johan K. Sandberg, David A. Price, Hans-Gustaf Ljunggren, Soo Aleman, Marcus Buggert

    News

    25th September 2020

    Data on additional cell tracks will be added during the autumn of 2020

    As work is progressing with the Karolinska KI/K COVID-19 Immune Atlas, data on additional immune cell types, including ILCs, neutrophils, unconventional T cells, B cells, and mononuclear phagocytes as well as on inflammatory soluble factors will be added during the autumn of 2020.

    Regulatory

    The present project has been approved by the Swedish Ethical Review Authority. All COVID-19 patients and healthy controls have provided consent to the study. All data are presented at a group aggregate level.

    Support

    The present project has supported by the Knut and Alice Wallenberg Foundation, Nordstjernan AB, Karolinska Institutet, and the Karolinska University Hospital.

    Licence

    The Karolinska KI/K COVID-19 Immune Atlas is licensed under the Creative Commons Attribution-ShareAlike 3.0 International License for all copyrightable parts of the present database.

    While it is encouraged to use this resources for research, proper citation of the content should be given in all cases.

    If uncertain about how to cite this source or if written approval is needed for a specific use that is otherwise restricted, please contact us.

    Other parts of this website, including photographs, drawings, design and code, are copyrighted and cannot be distributed or reused without permission.

    Citation

    If citing or displaying any content in any format, written or otherwise, including print or web publications, presentations, grant applications, websites, other online applications such as blogs, or other works, the following must be met:

    1. Include a reference to the primary publication (see list of papers).

    AND

    1. Include a reference to the present website: Karolinska KI/K COVID-19 Immune Atlas available from http://COVID19cellatlas.com

    Use of cookies

    This website is using Google Analytics for tracking statistics and user behavior. Google Analytics is a service provided by Google, Inc. IP addresses are anonymized before they are sent to Google. The data collected by Google Analytics is used to improve the website and will never be used for commercial purposes. Google Analytics uses cookies to store unique identifiers, so that metrics like unique users and length of visits can be provided. In addition to the cookies stored by Google Analytics, this webpage stores a cookie that remembers whether you have clicked on the "Close" button on the cookie notification at the bottom of the screen.

    What is a cookie?

    A cookie is a small piece of information that a website stores on your computer, and that is accessible by the website. Cookies can for example contain information about user preferences, so that the website appears as you want every time.

    How can I disable cookies?

    Most web browsers allow you to prevent cookies from being stored on your computer. We have listed links to descriptions for how to do this in some of the most popular web browsers:

    What cookies are used on this webpage?

    Name Expiration time Description
    _ga 2 years Used by Google Analytics to distinguish users.
    _gid 24 hours Used by Google Analytics to distinguish users.
    _gat_gtag_UA_166962014_1 1 minute Used to optimize network traffic to Google Analytics.
    privacy_read 1 year Indicates that the "Close" button has been clicked on the cookie information pop-up at the bottom of the screen, preventing this from being shown again.

    Contact

    Associate Professor Niklas Björkström, niklas.bjorkstrom@ki.se (science/research)

    Professor Hans-Gustaf Ljunggren, hans-gustaf.ljunggren@ki.se (science/research)

    Associate Professor Kristoffer Strålin, kristoffer.stralin@sll.se (science/clinic)

    MD Eivind Heggernes Ask, eivind.ask@rr-research.no (science/web)

          • Overview
          • Cell counts
          • Populations
          • Populations
          • Percentages
          • MFIs
          • Box plot
          • Volcano plot
          • Radar chart
          • Statistics

          Loading...

          This website uses cookies to operate properly. Click here to read more about how cookies and personal data is handled.

          Close